NDAINTRAVENOUSPOWDER
Approved
Sep 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
DAPTOMYCIN (daptomycin) by Sagent Pharmaceuticals is [see clinical pharmacology ()] . Approved for bacteremia, soft tissue infections, infective endocarditis and 6 more indications. First approved in 2017.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Daptomycin is a lipopeptide antibiotic administered intravenously as a powder for injection. It treats serious gram-positive bacterial infections including bacteremia, endocarditis, skin infections, and osteomyelitis by disrupting bacterial cell membrane function. It is particularly valuable for methicillin-resistant Staphylococcus aureus (MRSA) and other resistant gram-positive pathogens.
$0.692MPart D
PeakProduct is at peak lifecycle with modest Part D utilization (~2,000 claims annually), suggesting stable but limited ambulatory use; commercial teams likely focus on hospital/acute care channel management and specialist relationships.
Mechanism of Action
[see Clinical Pharmacology ()] .
Pharmacologic Class:
Lipopeptide Antibacterial
Indications (9)
Worked on DAPTOMYCIN at Sagent Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.